Table II.
Univariate analysis for serologic response rate in HM patients.
| Variable | Odds ratio | 95% CI | P |
|---|---|---|---|
| Treatment status | |||
| Last therapy ≤ 12 months prior | 1 | <0·001 | |
| Watch and wait strategy or last therapy > 12 months prior | 3·7 | 2·02–6·79 | |
| Type of treatment* | |||
| Other treatments | 1 | <0·001 | |
| Anti CD20 plus chemotherapy | 0·09 | 0·04–0·2 | |
| Sex | |||
| Male | 1 | 0·697 | |
| Female | 0·9 | 0·55–1·5 | |
| Age | |||
| <65 years | 1 | 0·471 | |
| ≥65 years | 1·21 | 0·72–2·01 | |
| Diagnosis | |||
| Aggressive B‐cell lymphomas | 1 | <0·001 | |
| Indolent B‐cell lymphomas or B‐cell lymphocytic leukaemia | 2·86 | 1·49–5·51 | |
| Hodgkin lymphoma | 6·72 | 2·5–18·09 | |
| Multiple myeloma | 29·56 | 1–29·32 | |
| T‐cell lymphomas | 5·43 | 8·2–106·49 | |
| Disease Status | |||
| Remission | 1 | 0·362 | |
| Active | 1·28 | 0·75–2·19 | |
| ALC | |||
| <800 cells/μl | 1 | <0·001 | |
| ≥800 cells/μl | 3·73 | 1·95–7·16 | |
| Not evaluable | 0·8 | 0·29–2·18 | |
| ANC | |||
| <1500 cells/μl | 1 | 0·652 | |
| ≥1500 cells/μl | 1·24 | 0·49–3·15 | |
| IgG | |||
| <600 mg/dl | 1 | 0·129 | |
| ≥600 mg/dl | 1·69 | 0·9–3·2 | |
| Not evaluable or not available | 2·05 | 0·99–4·23 | |
| IgA | |||
| <80 mg/dl | 1 | 0·296 | |
| ≥80 mg/dl | 1·55 | 0·85–2·83 | |
| Not evaluable or not available | 1·55 | 0·79–3·02 | |
| IgM | |||
| <40 mg/dl | 1 | 0·011 | |
| ≥40 mg/dl | 2·3 | 1·25–4·23 | |
| Not evaluable or not available | 2·21 | 1·17–4·19 |
ALC, absolute lymphocytic count; ANC, absolute neutrophilic count; CI, confidence interval.
*
This analysis was conducted only among patients who had received therapy in the last 12 months.